NeOnc’s Powerful Brain Cancer Pipeline Advances

The offering issued new securities, while the cash redemption eliminated potential dilution tied to the preferred shares.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) is scheduled to meet the FDA on November 17, 2026, about NEO212’s next clinical-development steps.

The End-of-Phase 1 meeting will cover a proposed Phase 2 patient population, trial design, endpoints and dose, and potential paths toward a marketing application. NEO212 completed Phase 1 dose escalation with a recommended Phase 2 dose of 610 mg. Reported tumor reduction of approximately 60% in one glioblastoma patient and approximately 16 months of stable disease in another patient with brain metastasis remain individual observations, not controlled evidence of efficacy. NEO212 also received UAE IND authorization.

For NEO100, Phase 2a six-month progression-free survival was 48.9% versus a prespecified 20% benchmark (p=0.0047). NeOnc completed a $15 million offering at $4.20 per share with warrants, then redeemed 6,000 Series A preferred shares for $6 million in cash.

11 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

How the balance works

Positive

• Major point$15 million offering completed at $4.20 per share. 16% of market cap
• Moderate pointNEO212 Phase 1 dose escalation completed, with a recommended Phase 2 dose of 610 mg.
• Moderate pointNEO100 six-month progression-free survival was 48.9% versus a prespecified 20% benchmark (p=0.0047).
• Minor pointNEO212 glioblastoma patient had approximately 60% tumor reduction and 21 months of disease control.
• Minor pointNEO212 patient with brain metastasis had stable disease for approximately 16 months.

6 minor points

• Minor pointNEO212 received UAE IND authorization.
• Minor pointNEO100 median overall survival was 26.09 months in the Phase 2a results.
• Minor pointNEO100 six-month survival was 86.7% in the Phase 2a results.
• Minor pointNEO100 partial response remained ongoing beyond 114 days.
• Minor point6,000 Series A preferred shares redeemed, eliminating related potential dilution without issuing common shares in the redemption.
• Minor pointNeOnc executives made approximately $629,000 in open-market share purchases after the NEO100 readout.

Negative

• Moderate pointSeries A redemption used $6 million in cash. 6.6% of market cap
• Minor pointNEO212 activity findings involve individual patients rather than controlled evidence of efficacy.
• Minor pointNew offering shares at $4.20 per share dilute existing holders; accompanying warrants have a $4.20 exercise price.

Key Figures

Scheduled FDA meeting: November 17, 2026 Recommended Phase 2 dose: 610 mg Maximum tolerated dose: 810 mg +3 more

Scheduled FDA meeting

November 17, 2026

In-person End-of-Phase 1 Type B meeting for NEO212

Recommended Phase 2 dose

610 mg

NEO212 Phase 1 dose-escalation program

Maximum tolerated dose

810 mg

Protocol-defined maximum in NEO212 Phase 1 dose escalation

Tumor reduction

Approximately 60%

Individual patient with recurrent glioblastoma; not controlled evidence of efficacy

Disease control

21 months

Individual patient with recurrent glioblastoma

Stable disease duration

Approximately 16 months

Individual patient with lung cancer metastatic to the brain

Key Terms

end-of-phase 1 type b meeting, maximum tolerated dose, accelerated-approval pathway, ind authorization, +2 more

6 terms

end-of-phase 1 type b meeting regulatory

"in-person End-of-Phase 1 Type B meeting concerning NEO212"

A U.S. Food and Drug Administration (FDA) "end-of-Phase 1" Type B meeting is a formal, scheduled discussion between a drug developer and regulators held after initial human safety testing (Phase 1). It focuses on the Phase 1 results, safety issues, and the design and data expectations for the next stage of development (Phase 2), serving like a checkpoint where the regulator and sponsor agree on what evidence is needed to move forward. This matters to investors because the meeting’s outcome can clarify timelines, required studies, and regulatory risk for a drug program.

maximum tolerated dose medical

"protocol-defined maximum tolerated dose of 810 mg"

Maximum tolerated dose is the highest amount of a substance, such as a medication or chemical, that can be used without causing unacceptable side effects or harm. It’s like finding the maximum speed you can drive without risking a ticket or accident. For investors, understanding this concept helps gauge how much risk or exposure is safe or sustainable in a given situation.

accelerated-approval pathway regulatory

"whether a future study could potentially support an accelerated-approval pathway"

A regulatory option that lets a drug or biologic reach the market sooner for serious or life-threatening conditions by relying on a surrogate or intermediate measure (like a lab result or tumor shrinkage) that is reasonably likely to predict real patient benefit, rather than waiting for longer-term outcomes. It matters to investors because it shortens time to sales and revenue but requires follow-up studies to confirm actual clinical benefit, similar to granting a provisional certificate based on early signs while a full exam continues.

ind authorization regulatory

"secured UAE IND authorization for NEO212"

Authorization of an Investigational New Drug (IND) is a regulator’s formal go-ahead that allows a company to begin testing a new drug or biologic in human clinical trials. It matters to investors because it moves a research program from laboratory and animal testing into human studies, serving as a regulatory milestone that signals progress, reduces one type of development uncertainty, and enables the company to pursue safety and effectiveness data needed for eventual market approval—much like receiving a building permit before construction can start.

idh1 wild-type medical

"recurrent IDH1 wild-type, MGMT-methylated glioblastoma"

A tumor described as “IDH1 wild-type” has the normal, unmutated form of the IDH1 gene rather than a cancer-associated mutation. Like saying a recipe is unchanged, it signals that the cancer lacks that specific genetic alteration used to classify tumors, predict outcomes, or qualify patients for treatments that target IDH1 mutations. Investors track this because it affects how common certain therapies or diagnostic tests may be and who is eligible for them.

mgmt-methylated medical

"IDH1 wild-type, MGMT-methylated glioblastoma"

MGMT-methylated indicates that the promoter region of the MGMT gene in tumor cells carries chemical methyl groups that reduce production of the MGMT DNA-repair enzyme. That reduced repair activity can make tumors more vulnerable to some DNA-damaging chemotherapies, so this biomarker is used in clinical trials and treatment decisions and can affect expected drug efficacy, trial outcomes, and commercial prospects for oncology therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

November 17 FDA Meeting Could Define the Next Phase for NEO212

DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212, its oral perillyl alcohol-temozolomide conjugate being developed for aggressive central nervous system cancers.

NeOnc plans to seek agency feedback on the proposed patient population, Phase 2 trial design, endpoints, dose selection and the evidence that could ultimately support a future marketing application. The company also intends to discuss potential registrational strategies and whether a future study could potentially support an accelerated-approval pathway.

NEO212 enters that discussion with a completed Phase 1 dose-escalation program and a defined recommended Phase 2 dose of 610 mg, following dose escalation to a protocol-defined maximum tolerated dose of 810 mg. The company has reported early signals of potential activity in heavily pretreated patients, including a patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma who experienced approximately a 60% tumor reduction and 21 months of disease control. Another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months. These observations remain individual-patient findings rather than controlled evidence of efficacy, making the design and outcome of larger studies critical. NeOnc has also secured UAE IND authorization for NEO212, creating an international clinical-development pathway alongside its U.S. regulatory discussions.

NeOnc CEO Amir Heshmatpour summarized the immediate objective: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.” The November meeting follows FDA written feedback earlier this year concerning NEO212’s chemistry, manufacturing and controls program and the planned transition from a capsule to a tablet formulation. That makes the upcoming discussion potentially important not only for clinical strategy, but also for clarifying the practical development path toward a larger study.

The NEO212 story is unfolding alongside meaningful progress from NeOnc’s lead program, NEO100. In August, the company reported topline Phase 2a results in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, with six-month progression-free survival of 48.9% versus a prespecified 20% benchmark (p=0.0047) and median overall survival of 26.09 months. NeOnc also reported that 86.7% of patients were alive at six months, five of 24 patients remained on treatment at the data cutoff, and one partial response remained ongoing beyond 114 days. The company said it plans to request an FDA Type B meeting to discuss a potential registrational pathway in this setting.

The company has also been building its financial position around those clinical catalysts. In September, NeOnc completed a $15 million registered direct offering priced at $4.20 per share, alongside warrants with a $4.20 exercise price. The financing involved new and existing healthcare-focused institutional investors, with proceeds designated for working capital, general corporate purposes and the redemption of Series A convertible preferred stock. Days later, NeOnc announced that it had redeemed all 6,000 outstanding Series A preferred shares for $6 million in cash, stating that the transaction eliminated the related potential dilution without issuing common shares in the redemption.

There has also been notable insider activity. NeOnc reported in September that its executives had made approximately $629,000 in open-market purchases following the positive NEO100 Phase 2a results, including CEO Amir Heshmatpour's purchase of an additional 35,000 shares for approximately $115,400 and 111,000 shares purchased by Heshmatpour since the August clinical readout. These purchases are factual disclosures of insider transactions and do not establish future clinical or market performance.

Wall Street has added another layer to the story. Roth Capital analyst Jonathan Aschoff initiated coverage of NeOnc in September with a reported $20 price target, while the research firm identified potential pivotal-trial starts for NEO100 and NEO212 as future development milestones. That is an analyst view rather than a company forecast or regulatory determination.

For NTHI, the November 17 FDA meeting now sits at the center of a broader sequence of catalysts: regulatory feedback for NEO212, continued advancement of NEO100 following its Phase 2a readout, potential registrational discussions, international development in the UAE and further financing and clinical execution.

For investors tracking the CNS biotech space, that makes November 17 a date with potentially significant implications for the company's development roadmap heading into 2027.

About InvestorsTape.com

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.

Contact
benh@investorstape.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.

General Disclaimer:

InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities.

This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will NeOnc discuss with the FDA about NEO212 on November 17, 2026?

NeOnc plans to seek FDA feedback on the proposed Phase 2 patient population, trial design, endpoints, dose selection and evidence that could support a future marketing application. The company also intends to discuss potential registrational strategies, including whether a future study could potentially support an accelerated-approval pathway.

What did NeOnc report from its NEO100 Phase 2a trial?

Six-month progression-free survival was 48.9% versus a prespecified 20% benchmark (p=0.0047), and median overall survival was 26.09 months. NeOnc also reported that 86.7% of patients were alive at six months, five of 24 patients remained on treatment at the data cutoff, and one partial response remained ongoing beyond 114 days.

Did NeOnc issue common shares to redeem its Series A preferred stock?

No common shares were issued in the redemption. NeOnc redeemed all 6,000 outstanding Series A preferred shares for $6 million in cash, eliminating the related potential dilution.